SG11201911617SA - T cells with reduced surface fucosylation and methods of making and using the same - Google Patents

T cells with reduced surface fucosylation and methods of making and using the same

Info

Publication number
SG11201911617SA
SG11201911617SA SG11201911617SA SG11201911617SA SG11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA SG 11201911617S A SG11201911617S A SG 11201911617SA
Authority
SG
Singapore
Prior art keywords
cells
making
methods
same
reduced surface
Prior art date
Application number
SG11201911617SA
Other languages
English (en)
Inventor
Nicole Okeley
Jessica Field
Shyra Gardai
Ryan Heiser
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201911617SA publication Critical patent/SG11201911617SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
SG11201911617SA 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same SG11201911617SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516536P 2017-06-07 2017-06-07
PCT/US2018/036067 WO2018226701A1 (en) 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same

Publications (1)

Publication Number Publication Date
SG11201911617SA true SG11201911617SA (en) 2020-01-30

Family

ID=62751563

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911617SA SG11201911617SA (en) 2017-06-07 2018-06-05 T cells with reduced surface fucosylation and methods of making and using the same

Country Status (17)

Country Link
US (2) US11891644B2 (he)
EP (1) EP3634427A1 (he)
JP (1) JP7245177B2 (he)
KR (1) KR102687149B1 (he)
CN (1) CN110740734A (he)
AU (1) AU2018282225B2 (he)
BR (1) BR112019025775A2 (he)
CA (1) CA3065524A1 (he)
EA (1) EA201992875A1 (he)
IL (1) IL271012B2 (he)
MA (1) MA50865A (he)
MX (1) MX2019014584A (he)
SG (1) SG11201911617SA (he)
TW (1) TW201903144A (he)
UA (1) UA128783C2 (he)
WO (1) WO2018226701A1 (he)
ZA (1) ZA201907623B (he)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
MX2023010902A (es) 2021-03-18 2023-09-27 Seagen Inc Liberacion selectiva de farmacos a partir de conjugados internalizados de compuestos biologicamente activos.
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
PT2608796T (pt) 2010-08-05 2019-02-25 Seattle Genetics Inc Inibição de fucosilação de proteínas in vivo utilizando análogos de fucose
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
WO2015120096A2 (en) 2014-02-04 2015-08-13 Marc Better Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
CN113046312A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
EP3169773B1 (en) 2014-07-15 2023-07-12 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
SG10201902168PA (en) 2014-09-09 2019-04-29 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
EP3702447A1 (en) 2015-10-20 2020-09-02 Kite Pharma, Inc. Methods of preparing t cells for t cell therapy
SG11201804263PA (en) 2015-12-04 2018-06-28 Seattle Genetics Inc Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Also Published As

Publication number Publication date
BR112019025775A2 (pt) 2020-06-23
KR20200015580A (ko) 2020-02-12
KR102687149B1 (ko) 2024-07-24
EA201992875A1 (ru) 2020-03-25
UA128783C2 (uk) 2024-10-23
IL271012B1 (he) 2023-08-01
MA50865A (fr) 2020-04-15
JP7245177B2 (ja) 2023-03-23
ZA201907623B (en) 2024-04-24
AU2018282225A1 (en) 2019-12-12
MX2019014584A (es) 2020-02-07
US20240117400A1 (en) 2024-04-11
TW201903144A (zh) 2019-01-16
CN110740734A (zh) 2020-01-31
EP3634427A1 (en) 2020-04-15
AU2018282225B2 (en) 2024-06-13
IL271012A (he) 2020-01-30
US20200149082A1 (en) 2020-05-14
US11891644B2 (en) 2024-02-06
IL271012B2 (he) 2023-12-01
JP2020523014A (ja) 2020-08-06
CA3065524A1 (en) 2018-12-13
WO2018226701A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
HK1250481A1 (zh) 經過修飾的t細胞及其製備和使用方法
IL262772A (he) תאים שעברו הנדסה גנטית ושיטות להכנתם
EP3601528A4 (en) CELLS AND METHODS OF USE AND PRODUCTION OF THEM
IL255801A (he) ננומבנים ליפוזומלים ושיטות להכנה ולשימוש בהם
SG11202004116QA (en) T cell manufacturing compositions and methods
EP3231024A4 (en) Electrochemical cell and method of making the same
EP3024417A4 (en) GRAFT HAVING AN EXPANDABLE AREA AND METHODS OF MAKING AND USING THE GRAFT
EP3093889B8 (en) Solar cell and method of manufacturing the same
EP3735303A4 (en) WING AND PROCESS
EP3443608A4 (en) ELECTROCHEMICAL CELLS WITH DESIGNED FLOW FIELDS AND MANUFACTURING METHODS THEREOF
EP3327793C0 (en) SOLAR CELL AND ITS MANUFACTURING METHOD
IL280240A (he) תאי t המכילים nef ושיטות לייצורם
EP3374559A4 (en) NONWOVEN HAVING ENHANCED ABRASION RESISTANCE AND MANUFACTURING METHOD THEREOF
EP3538250A4 (en) PC STRUCTURES WITH SUPPORTED POLYAMINES AND METHOD FOR PRODUCING THE SUPPORTED POLYAMINS
EP3516127A4 (en) STRUCTURE AND MANUFACTURING METHOD THEREOF
HK1244512A1 (zh) 突變型smoothened及其使用方法
SG11201900459RA (en) Mg53 mutants, methods of making the same, and uses thereof
EP3096892A4 (en) Carbon nanotube-coated substrates and methods of making the same
IL271012A (he) תאי t עם פוקוזילצית משטח מופחתת ושיטות להכנה ולשימוש בהם
EP3218477A4 (en) Compositions and methods for expressing polypeptides on the surface of cells
EP3307873A4 (en) Hematopoietic cells and methods of using and generating the same
IL250554A0 (he) מצעים משופרים המעודדים צמיחת עצם ושיטות להכנתם
EP3651606A4 (en) PRECIOUS STONE COATINGS AND RELATED MANUFACTURING AND USE PROCEDURES
EP3515207A4 (en) NATURAL WATER ESSENCE AND METHOD FOR PRODUCING IT
EP3494217A4 (en) LMP-1 EXPRESSING CELLS AND METHODS OF USE